A study published in the Lancet Oncology by an international team led by Prof Rob E. Coleman (University of Sheffield) and Prof Roger R. Gomis (IRB Barcelona) identifies the effect of MAF amplification on the outcome of treatment with adjuvant zoledronic acid in early breast cancer.
This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and both reduce disease recurrence and deaths from breast cancer.
Inbiomotion, an IRB Barcelona spin off company and financed by venture investors Ysios Capital and Caixa Capital Risc, will soon start a confirmatory trial.
The Secretary of State for R&D+i, Carmen Vela, chaired the kickoff meeting of the new Severo Ochoa and Maria Maeztu Alliance of Excellence.
The alliance’s target is to internationally promote and strengthen the centres and units accredited with this distinction, to give their research a higher profile.
Professor Antonio Zorzano is the president of the FEBS3+ Congress as well as programme head at IRB Barcelona and the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre (CIBERDEM).
The labs headed by Angel R. Nebreda, Ernest Giralt and Roger Gomis secure funding for further development of three medical applications.
The three projects will receive 220,000 euros from the "Knowledge Industry" programme, which is run by the Catalan Government and cofunded by ERDFs.
Today, the highest representatives of the universities and research centres of Catalonia (60 institutions, representing around 90% of the university and research community) have met to assess the current situation in Catalonia resulting from the actions of the Spanish Government over the last few days. The meeting was also attended by representatives of the trade unions and students' associations.
It has been concluded that the good repute of the academic and research institutions of Catalonia has been undermined by their inclusion by the Ministry of Finance and Civil Service in a list of institutions whose budgetary powers have been rescinded and which are, therefore, in the eyes...
The only one of its kind in Spain, the Master offers practical training in experimental research in various disciplines at centers of excellence including IRB Barcelona.
Researchers at IRB Barcelona reveal the capacity of epithelial-derived tumours to grow in the absence of a microenvironment.
Featured on the cover of the journal Proceedings of the National Academic of Sciences (PNAS), the study identifies the cell types and molecular mechanism involved in tumour initiation and growth.
The results of this study contribute to our understanding of the internal mechanisms of the tumour, which may provide a therapeutic target.
ERC Starting Grants support young talented researchers over 5 years.
The IRB Barcelona group leader will focus on the genomes of hypermutated tumours to detect cancer vulnerabilities.
Genomic instability is the main risk factor for tumour development in humans. Therefore understanding its origin and exploring therapeutic targets is paramount.
Histone 1 silences a region of the genome that causes irreparable DNA damage when translated and is lethal for the organism.
Stem cell functions continue to be governed by day and night cycles (circadian rhythms) during ageing, but their rhythms become devoted to tissue repair and not to the maintenance of tissue tone.
The two studies published in Cell and headed by Salvador Aznar Benitah at IRB Barcelona reject the scientific dogma associating ageing with the loss of stem cell circadian rhythm.
A low-calorie diet delays alterations in the rhythmic functions of stem cells and slows down ageing.